Recursion announced on November 5 2025 that its board approved a leadership transition plan effective January 1 2026, appointing Dr. Najat Khan as CEO and President and moving co‑founder Chris Gibson to Chairman of the Board. The move follows a unanimous board vote and reflects confidence in Khan’s experience scaling AI‑driven biopharma.
The same day the company released its Q3 2025 earnings, which showed a revenue miss and a widening net loss. The report highlighted that the company’s operating results fell short of analyst expectations, underscoring the challenges Recursion faces in translating its platform into commercial revenue.
Investors reacted negatively to the combined news of the leadership change and the earnings miss. Market participants expressed concerns about potential operational disruption during the transition and the company’s ability to meet its financial targets in the near term.
In a statement, Dr. Rob Hershberg, Recursion’s current Chairman, said the board’s unanimous decision to appoint Khan was driven by her strategic acumen and proven track record of converting new science into value. Dr. Najat Khan added that she is honored to lead the company and will build on the foundation laid by Gibson, emphasizing the platform’s ability to decode biology at scale. Dr. Chris Gibson noted his confidence in Khan’s leadership and his commitment to guiding the company as Chairman.
The transition is positioned to accelerate Recursion’s platform monetization and pipeline development. Khan’s background at Johnson & Johnson’s Janssen Pharmaceuticals, where she integrated data science and AI into R&D strategy, is expected to strengthen the company’s partnership programs and commercial execution. The company’s strong cash position of approximately $785 million as of October 9 2025 provides a runway through the end of 2027, giving management flexibility to invest in growth initiatives while navigating the current earnings miss.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.